Krystal Biotech Inc. (KRYS)
NASDAQ: KRYS · Biological Products, (No Diagnostic Substances) · Pittsburgh, PA
Our rating: Positive
Call changed from Neutral to Positive at $305.03, moderate conviction, November 3, 2026.
Breaks if: The positive call breaks if revenue growth decelerates below 15% year-over-year in two consecutive quarterly reports within the next twelve months — that would indicate the franchise is approaching its rare-disease ceiling faster than the 44.6× multiple assumes. The call moves toward Conviction if management discloses a second program entering late-stage development (Phase 3 or NDA-ready), establishing the gene therapy platform as a multi-asset franchise with a credible growth vector beyond the current lead product.
Key figures
| Market value | $9.2B |
|---|---|
| Revenue, last 12 months | $470M |
| Net income, last 12 months | $225M |
| Free cash flow, last 12 months | $310M |
| Price to earnings | 40.7× |
| Free cash flow yield | 3.4% |
| Dividend yield | 0.0% |
| Operating margin | 48.4% |
| Return on equity | 17.5% |
| Beta to the S&P 500 | 0.88 |
| Volatility, annualized | 41.5% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $127M | 30.2% | $2.05 | $90M |
| June 30, 2026 | $119M | 24.1% | $1.79 | $71M |
| March 31, 2026 | $116M | 31.9% | $1.83 | $73M |
| December 31, 2025 | $107M | 17.5% | $1.70 | $75M |
| September 30, 2025 | $98M | 16.6% | $2.66 | $38M |
| June 30, 2025 | $96M | 36.6% | $1.29 | $51M |
| March 31, 2025 | $88M | 94.9% | $1.20 | $25M |
| December 31, 2024 | $91M | 116.3% | $1.53 | $52M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.13B: Claude 82%, Gemini 90%, Mistral 90%
- Diluted earnings per share are at least $1.70: Claude 65%, Gemini 95%, Mistral 85%
- Free cash flow for the quarter is at least $0.08B: Claude 55%, Gemini 80%, Mistral 75%
18 ledger entries and 24 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.